

**Fortis Healthcare Limited**

Tower-A, Unitech Business Park, Block-F,
South City 1, Sector – 41, Gurgaon,
Haryana – 122 001 (India)

Tel : 0124 492 1033

Fax : 0124 492 1041

Emergency : 105010

Email : secretarial@fortishealthcare.com

Website : www.fortishealthcare.com

FHL/SEC/2022-23

May 20, 2022

**The National Stock Exchange of India Ltd.
Corporate Communications Department
“Exchange Plaza”, 5th Floor, Bandra-Kurla
Complex, Bandra (East), Mumbai – 400051
Scrip Symbol: FORTIS**

**BSE Limited
Corporate Services Department
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001
Scrip Code:532843**

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

Dear Madam / Sir,

This is in continuation of our intimation dated October 18, 2018, December 22, 2018, March 20, 2019, November 13, 2020, November 20, 2020 and April 15, 2021 with respect to an *ad-interim ex-parte* order passed by Securities and Exchange Board of India (“SEBI”) in the matter relating to the alleged diversion of funds from the Company by its erstwhile promoters. SEBI has now issued an adjudication order no. Order/GR/KG/2022-23/16420-16458 (“Order”) dated May 18, 2022, *inter-alia* in respect of Escorts Heart Institute and Research Centre Limited – a wholly owned subsidiary of Fortis Healthcare Limited – in the aforesaid matter. The management and Board of the Company that was newly constituted after NTK Ventures Pte. Ltd. (a wholly owned subsidiary of IHH Healthcare Berhad) became promoters of the Company, are evaluating the Order in detail, in consultation with their legal advisors.

The detailed disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed as ‘Annexure A’.

This is for your information and record.

Thanking you,

Yours Faithfully

For **Fortis Healthcare Limited**

**MM Jain
Company Secretary & Compliance Officer
M. No. - F9598**

FORTIS HEALTHCARE LIMITED

Regd. Office : Fortis Hospital, Sector 62, Phase – VIII, Mohali – 160062
Tel : 0172-5096001, Fax : 0172-5096221, CIN : L85110PB1996PLC045933

Annexure A
Disclosures as required under Regulation 30
of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Regulatory action(s) with impact		
S. No	Particulars	Details
1.	The details of any change in the status and / or any development in relation to such proceedings.	In the matter relating to the alleged diversion of funds from the Company by its erstwhile promoters, the adjudicating officer of SEBI has issued an adjudication order (“ Order ”) in respect of <i>inter-alia</i> Escorts Heart Institute and Research Limited (“ EHIRCL ”) – a wholly owned subsidiary of Fortis Healthcare Limited wherein a penalty of Rs. 1 Crore has been imposed on EHIRCL for violations of certain provisions of the SEBI Act, 1992 and the SEBI (Prohibition of Fraudulent and Unfair Trade Practices relating to Securities Market) Regulations, 2003. In its Order, SEBI has specifically highlighted as mitigating factors – the fact that EHIRCL is presently under a completely new management and the revamped management has taken steps against the erstwhile management for the fraud perpetrated under its watch.
2.	In the case of litigation against key management personnel or its promoter or ultimate person in control, regularly provide details of any change in the status and / or any development in relation to such proceedings.	Refer point no. 1 above.
3.	In the event of settlement of the proceedings, details of such settlement including - terms of the settlement, compensation/penalty paid (if any) and impact of such settlement on the financial position of the listed entity.	Not Applicable.